HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe

Journal of Hepatology

Volumn 66, Issue 2, 2017, Pages 282-287

  Ingiliz, Patrick ^a   Martin, Thomas C ^b   Rodger, Alison ^c   Stellbrink, Hans Jürgen ^d   Mauss, Stefan ^e   Boesecke, Christoph ^f   Mandorfer, Mattias ^g   Bottero, Julie ^h   Baumgarten, Axel ^a   Bhagani, Sanjay ^c   Lacombe, Karine ^h,i   Nelson, Mark ^b,j   Rockstroh, Jürgen K ^f  

^a Center for Infectiology (CIB)   (Germany)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d Infektionsmedizinisches Centrum Hamburg   (Germany)

^e Center for HIV and Hepatogastroenterology   (Germany)

^f UNIVERSITY OF BONN   (Germany)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h HÔPITAL SAINT ANTOINE   (France)

ⁱ SORBONNE UNIVERSITÉ   (France)

^j IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

more..

Author keywords

Acute hepatitis C; HCV reinfection; HCV therapy; HIV HCV coinfection; Spontaneous clearance; SVR

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON; RIBAVIRIN; VIRUS RNA; ANTIVIRUS AGENT;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; AUSTRIA; CLINICAL EVALUATION; COHORT ANALYSIS; CONFIDENCE INTERVAL; FOLLOW UP; FRANCE; GERMANY; HAZARD RATIO; HEPATITIS C; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; MULTICENTER STUDY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REINFECTION; RETROSPECTIVE STUDY; UNITED KINGDOM; VIRAL CLEARANCE; VIRUS LOAD; WESTERN EUROPE; COMMUNICABLE DISEASE CONTROL; EUROPE; FEMALE; HEPACIVIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; MALE HOMOSEXUALITY; MIDDLE AGED; MIXED INFECTION; STATISTICS AND NUMERICAL DATA; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; COINFECTION; COMMUNICABLE DISEASE CONTROL; EUROPE; FEMALE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV SEROPOSITIVITY; HOMOSEXUALITY, MALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED;

EID: 85004074767     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.09.004     Document Type: Article

References (40)

1. [1] Smith, C.J., Ryom, L., Weber, R., Morlat, P., Pradier, C., Reiss, P., et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet 384 (2014), 241–248.
2. [2] Ioannou, G.N., Bryson, C.L., Weiss, N.S., Miller, R., Scott, J.D., Boyko, E.J., The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology 57 (2013), 249–257.
3. [3] Rosenthal, E., Roussillon, C., Salmon-Ceron, D., Georget, A., Henard, S., Huleux, T., et al. Liver-related deaths in HIV-infected patients between 1995 and 2010 in France: the Mortavic 2010 study in collaboration with the Agence Nationale de Recherche sur le SIDA (ANRS) EN 20 Mortalite 2010 survey. HIV Med 16 (2015), 230–239.
4. [4] Boesecke, C., Grint, D., Soriano, V., Lundgren, J.D., d'Arminio Monforte, A., Mitsura, V.M., et al. Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected?. Liver Int 35 (2015), 2384–2391.
5. [5] Wandeler, G., Schlauri, M., Jaquier, M.E., Rohrbach, J., Metzner, K.J., Fehr, J., et al. Incident hepatitis C virus infections in the swiss HIV cohort study: changes in treatment uptake and outcomes between 1991 and 2013. Open Forum Infect Dis, 2, 2015, ofv026.
6. [6] Danta, M., Brown, D., Bhagani, S., Pybus, O.G., Sabin, C.A., Nelson, M., et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. Aids 21 (2007), 983–991.
7. [7] van de Laar, T.J., Matthews, G.V., Prins, M., Danta, M., Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. Aids 24 (2010), 1799–1812.
8. [8] Urbanus, A.T., van de Laar, T.J., Stolte, I.G., Schinkel, J., Heijman, T., Coutinho, R.A., et al. Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. Aids 23 (2009), F1–F7.
9. [9] Boesecke, C., Rockstroh, J.K., Treatment of acute hepatitis C infection in HIV-infected patients. Curr Opin HIV AIDS 6 (2011), 278–284.
10. [10] Urbanus, A.T., Van De Laar, T.J., Geskus, R., Vanhommerig, J.W., Van Rooijen, M.S., Schinkel, J., et al. Trends in hepatitis C virus infections among MSM attending a sexually transmitted infection clinic; 1995–2010. Aids 28 (2014), 781–790.
11. [11] Naggie, S., Cooper, C., Saag, M., Workowski, K., Ruane, P., Towner, W.J., et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 373 (2015), 705–713.
12. [12] Sulkowski, M.S., Eron, J.J., Wyles, D., Trinh, R., Lalezari, J., Wang, C., et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA 313 (2015), 1223–1231.
13. [13] Wyles, D.L., Ruane, P.J., Sulkowski, M.S., Dieterich, D., Luetkemeyer, A., Morgan, T.R., et al. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med 373 (2015), 714–725.
14. [14] Rockstroh, J.K., Nelson, M., Katlama, C., Lalezari, J., Mallolas, J., Bloch, M., et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV 2 (2015), e319–e327.
15. [15] Martin, N.K., Vickerman, P., Grebely, J., Hellard, M., Hutchinson, S.J., Lima, V.D., et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 58 (2013), 1598–1609.
16. [16] Martin, N.K., Thornton, A., Hickman, M., Sabin, C., Nelson, M., Cooke, G.S., et al. Can hepatitis C virus (HCV) direct-acting antiviral treatment as prevention reverse the HCV epidemic among men who have sex with men in the United Kingdom? Epidemiological and modeling insights. Clin Infect Dis 62 (2016), 1072–1080.
17. [17] Grebely, J., Prins, M., Hellard, M., Cox, A.L., Osburn, W.O., Lauer, G., et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis 12 (2012), 408–414.
18. [18] Sacks-Davis, R., Grebely, J., Dore, G.J., Osburn, W., Cox, A.L., Rice, T.M., et al. Hepatitis C virus reinfection and spontaneous clearance of reinfection-the InC3 study. J Infect Dis 212 (2015), 1407–1419.
19. [19] Martin, T.C., Martin, N.K., Hickman, M., Vickerman, P., Page, E.E., Everett, R., et al. Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. Aids 27 (2013), 2551–2557.
20. [20] Ingiliz, P., Krznaric, I., Stellbrink, H.J., Knecht, G., Lutz, T., Noah, C., et al. Multiple hepatitis C virus (HCV) reinfections in HIV-positive men who have sex with men: no influence of HCV genotype switch or interleukin-28B genotype on spontaneous clearance. HIV Med 15 (2014), 355–361.
21. [21] Simmons, B., Saleem, J., Hill, A., Riley, R.D., Cooke, G.S., Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. Clin Infect Dis 62 (2016), 683–694.
22. [22] Lambers, F.A., Prins, M., Thomas, X., Molenkamp, R., Kwa, D., Brinkman, K., et al. Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM. Aids 25 (2011), F21–F27.
23. [23] Sarrazin C, Isakov V, Svarovskaia E, Martin R, Chodavarapu K, Hedskog C, et al., editor HCV reinfection in phase 3 studies of sofosbuvir. In: 50th Annual Meeting of the European Association for the Study of the Liver; April 22–26, 2014; Vienna, Austria, Abstract P0063.
24. [24] Lanford, R.E., Guerra, B., Chavez, D., Bigger, C., Brasky, K.M., Wang, X.H., et al. Cross-genotype immunity to hepatitis C virus. J Virol 78 (2004), 1575–1581.
25. [25] Osburn, W.O., Fisher, B.E., Dowd, K.A., Urban, G., Liu, L., Ray, S.C., et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 138 (2010), 315–324.
26. [26] Thomson, E.C., Fleming, V.M., Main, J., Klenerman, P., Weber, J., Eliahoo, J., et al. Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut 60 (2011), 837–845.
27. [27] Boesecke, C., Ingiliz, P., Reiberger, T., Stellbrink, H.J., Bhagani, S., Page, E., et al. Dual treatment of acute HCV infection in HIV co-infection: influence of HCV genotype upon treatment outcome. Infection 44 (2016), 93–101.
28. [28] Bourne, A., Reid, D., Hickson, F., Torres-Rueda, S., Weatherburn, P., Illicit drug use in sexual settings (’chemsex’) and HIV/STI transmission risk behaviour among gay men in South London: findings from a qualitative study. Sex Transm Infect 91 (2015), 564–568.
29. [29] Daskalopoulou, M., Rodger, A., Phillips, A.N., Sherr, L., Speakman, A., Collins, S., et al. Recreational drug use, polydrug use, and sexual behaviour in HIV-diagnosed men who have sex with men in the UK: results from the cross-sectional ASTRA study. Lancet HIV 1 (2014), e22–e31.
30. [30] Grady, B.P., Schinkel, J., Thomas, X.V., Dalgard, O., Hepatitis C virus reinfection following treatment among people who use drugs. Clin Infect Dis 57 (2013), S105–S110.
31. [31] Aspinall, E.J., Corson, S., Doyle, J.S., Grebely, J., Hutchinson, S.J., Dore, G.J., et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis 57 (2013), S80–S89.
32. [32] Vickerman, P., Grebely, J., Dore, G.J., Sacks-Davis, R., Page, K., Thomas, D.L., et al. The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design. J Infect Dis 205 (2012), 1342–1350.
33. [33] Kokordelis, P., Kramer, B., Korner, C., Boesecke, C., Voigt, E., Ingiliz, P., et al. An effective interferon-gamma-mediated inhibition of hepatitis C virus replication by natural killer cells is associated with spontaneous clearance of acute hepatitis C in human immunodeficiency virus-positive patients. Hepatology 59 (2014), 814–827.
34. [34] Schulze Zur Wiesch, J., Ciuffreda, D., Lewis-Ximenez, L., Kasprowicz, V., Nolan, B.E., Streeck, H., et al. Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. J Exp Med 209 (2012), 61–75.
35. [35] Pestka, J.M., Zeisel, M.B., Blaser, E., Schurmann, P., Bartosch, B., Cosset, F.L., et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A 104 (2007), 6025–6030.
36. [36] Kim, A.Y., Kuntzen, T., Timm, J., Nolan, B.E., Baca, M.A., Reyor, L.L., et al. Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes. Gastroenterology 140 (2011), 686–696, e1.
37. [37] Page, K., Hahn, J.A., Evans, J., Shiboski, S., Lum, P., Delwart, E., et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis 200 (2009), 1216–1226.
38. [38] Tillmann, H.L., Thompson, A.J., Patel, K., Wiese, M., Tenckhoff, H., Nischalke, H.D., et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 139 (2010), 1586–1592, 92, e1.
39. [39] Farci, P., Shimoda, A., Coiana, A., Diaz, G., Peddis, G., Melpolder, J.C., et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 288 (2000), 339–344.
40. [40] Abdelrahman, T., Hughes, J., Main, J., McLauchlan, J., Thursz, M., Thomson, E., Next-generation sequencing sheds light on the natural history of hepatitis C infection in patients who fail treatment. Hepatology 61 (2015), 88–97.